RxDoctor Payments Data

Mark Juretic, MD

Internal Medicine · Santa Barbara, CANPI 1689778029

Payments from drug & device makers

$779in general payments, 2019–2025

Across 31 payments — averaging $25.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$236
  • AbbVie$191
  • AstraZeneca$86
  • Merck$68
  • Johnson & Johnson$48
  • Amarin Pharma, Inc.$43
  • plus $108 from 4 others

What the payments were for

  • Food & beverage$779100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$779 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$122,345
Medicare patients
404
Services billed
1,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$80,115
MounjaroTirzepatide31$39,891
JardianceEmpagliflozin43$38,644
XareltoRivaroxaban18$28,940
JanuviaSitagliptin Phosphate13$20,470
OzempicSemaglutide13$18,587
TrulicityDulaglutide12$11,117
PremarinEstrogens, Conjugated19$7,065
Atorvastatin Calcium435$4,026
Levothyroxine Sodium201$3,146
Advair HfaFluticasone Propion/Salmeterol11$3,027
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide61$2,738
Gabapentin147$2,689
Fluticasone-SalmeterolFluticasone Propion/Salmeterol21$2,398
Losartan Potassium195$2,172

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$20$87,180110 claims
Lilly USA, LLCMounjaro, Trulicity$36$51,00843 claims
Boehringer IngelheimJardiance$236$38,64443 claims
Johnson & JohnsonXarelto$48$28,94018 claims
MerckJanuvia$68$20,47013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →